Cetuximab: Its use in combination with radiation therapy and chemotherapy in the multimodality treatment of head and neck cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 2, 2008, Pages 76-83

  Wagner, Timothy D ^a   Yang, Gary Y ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cetuximab; Concurrent chemotherapy and radiation; Epidermal growth factor receptor; Radiation therapy; Squamous cell carcinoma of the head and neck; Targeted therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; IRINOTECAN; MATUZUMAB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; PROTEIN BAX; PROTEIN BCL 2; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ZALUTUMUMAB;

ACNE; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; HYPOMAGNESEMIA; HYPOPHARYNX CANCER; INJECTION SITE REACTION; LARYNX CANCER; LOADING DRUG DOSE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OROPHARYNX CANCER; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 55649117035     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208784638776     Document Type: Review

References (82)

1. Seiwert TY, Cohen EE. State-of-the-art management of locally advanccd head and neck cancer. Br J Cancer 2005; 92: 1341-1348.
2. Blick SK, Scott LJ. A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67: 2585-2607.
3. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
4. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007; 254: 165-177.
5. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-1948.
6. Salomon DS, Brandt H, Ciardiello F, Normanno NI. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
7. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548-5557.
8. Mahtani RL, Macdonald JS. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist 2008; 13: 39-50.
9. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31-53.
10. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-787.
11. Yu X, Sharma KD, Takahashi T, Iwamoto H, Mekada E. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand induced EGFR signaling. Mol Biol Cell 2002; 13: 2547-2557.
12. Rivera G, Vega-Villegas ME, López-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008; 19: 99-113.
13. Kopp R, Rothbauer E, Mueller E, Schildberg FW, Jauch KW, Pfeiffer A. Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis Colon Rectum 2003; 46: 1391-1399.
14. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-569.
15. Panikkar RP, Astsaturov I, Langer CJ. The emerging role of cetuximab in head and neck cancer: a 2007 perpective. Cancer Invest 2008; 26: 96-103.
16. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002-1007.
17. Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog Allergy 1988; 45: 147-160.
18. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-1878. 19 Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys 2004; 58: 959-965.
19. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
20. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11.
21. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-8.
22. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1: 511-29.
23. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30: 255-268.
24. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53: 4322-4328.
25. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18: 427-436.
26. Bier H, Hoffmann T, Haas I, van Lierop A. Anti (epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998; 46: 167-173.
27. Fan Z, Lu Y, Wu X, DeBlasio A, Koff A, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269: 27595-27602.
28. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibodydependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 781-787.
29. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13: 506-513.
30. Kiyota A, Shintani S, Mihara M, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 2002; 63: 92-98.
31. Wu X, Rubin M, Fan Z, et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996; 12: 1397-1403.
32. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
33. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-1530.
34. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor bloackage by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89: 74-82.
35. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19: 419-427.
36. Balaban N, Moni J, Shannon M, Dang L, Murphy E, Goldkorn T. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1996; 1314: 147-56.
37. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 1191-7.
38. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor tngiogenesis. Clin Cancer Res 2000; 6: 2166-74.
39. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-8.
40. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA dependent protein kinase. J Biol Chem 2005; 280: 31182-31189.
41. Head and Neck Cancers, V1. 2007, National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™, accessed March 10, 2008 http://www.nccn.org/professionals/physician_gls/PDF/ head-and-neck.pdf.
42. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19: 3234-3243.
43. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
44. Bonner JA, Harari PM, Giralt J, et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. J Clin Oncol, 2005 ASCO Annu Meet Proc. Vol 23, No. 16S, Part I of II (June 1 Suppl), 2005: 5533.
45. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191-2197.
46. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
47. Vokes EE, Stenson KM. Therapeutic options for laryngeal cancer. N Engl J Med 2003; 349: 2087-2089.
48. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-1078.
49. Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/ IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 2007 ASCO Annu Meet Proc Vol 25, No. 18S (June 20 Suppl), 2007: 6015.
50. Gibson MD, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
51. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. The Oncologist 2005; 10: 250-261.
52. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-1333.
53. Prewett M, Bassi R, Carrick FE, et al. Cetuximab (ERBITUX) enhances clinical efficacy of oxaliplatin in human colon carcinoma xenografts and reverses oxaliplatin resistance. 2005 AACR-NCI-EORTC Annual Meeting, Philadelphia, USA (2005).
54. Ellis LM, Hoff PM. Targeting the epidermal growth factor receptor: An important incremental step in the battle against colorectal cancer. J Clin Oncol 2004; 22: 1177-1179.
55. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7: 1204-13.
56. Kies MS, Ghebremichael MS, Katz TL, Herbst RS, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007 ASCO Annu Meet Proc Vol 25, No. 18S (June 20 Supplement), 2007: 6024.
57. Burtness B, Goldwasser MA, Flood W, et al. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol 2005; 23: 8646-8654.
58. Bouris J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-2872.
59. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized phase III (EXTREME) study. J Clin Oncol 2007 ASCO Annu Meet Proc Vol 25, No. 18S (June 20 Supplement), 2007: 6091.
60. Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of Cetuximab given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmco-dynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2006 ASCO Annu Meet Proc Vol 24, No.18S, (20 June Supplement), 2006: 3085.
61. Hitt R, Irigoyen A, Nuñez J, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/ recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish head and neck cancer group (TTC): J Clin Oncol 2007 ASCO Annu Meet Proc Vol 25, No. 18S (June 20 Supplement), 2007: 6012.
62. León X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17: 418-24.
63. Vermorken J, Bourhis J, Trigo J, et al. Cetuximab in recurrent/ metastatic squamous cell carcinoma of the head and neck refractory to first-line platinum-based therapies. J Clin Oncol 2005 ASCO Annu Meet Proc Vol 23, No. 16S, (June 1 Supplement), 2005: 5505.
64. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-77.
65. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/ot matastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy. J Clin Oncol 2007; 25 2171-7.
66. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002; 29(suppl 14): 55-60.
67. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.
68. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19: 142-9.
69. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
70. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J Clin Oncol, 2007 ASCO Annu Meet Proc Vol 25, No. 18S (June 20 Suppl), 2007: 4037.
71. ImClone Systems, Inc. and Bristol Myers-Squibb Company. Erbitux (tm) (Cetuximab) package insert. Branchburg, NJ: ImClone systems, Inc. 2006.
72. Siena S, Glynne-Jones R, Thaler J, et al. MABEL: a large multinational study of cetuximab plus irinotecan in irinotecan-resistant metastatic colorectal cancer: Update on infusing related. reactions (IRR). Proceedings 2007 Gastrointestinal Cancers Symposium. Abstract: 353.
73. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion, reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25: 2644-2648.
74. Grávalos C, Sastre J, Aranda E, Massutí B, Vega-Villegas ME, Gómez A, et al. Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent Cetuximab as first-line treatment. J Clin Oncol 2007 ASCO Annual Meet Proc Vol 25, No.18S, (June 20), 2007: 4120.
75. Radiation Therapy Oncology Group, RTOG 0522: A phase III trial of concurrent accelerated radiationand cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (C225) [followed by surgery for selected cases] for stage III and IV head and neck carcinomas, accessed March 10, 2008. http://www.rtog.org/members/ protocols/0522/0522.pdf. 77 Radiation Therapy Oncology Group, RTOG 0234: A phase II randomized trial of surgery followed by chemoradiotherapy plus C225 (cetuximab) for advanced squamous cell carcinoma of the head and neck, accessed March 10, 2008. http://www.rtog.org/members/ protocols/0234/0234.pdf.
76. European Organization for Research and Treatment of Cancer, EORTC 24061: Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies, accessed March 10, 2008. http://www.eortc.be/protoc/ listprot.asp?kind=sites&site=42.
77. Harari P.M., Chinnaiyan, P., Huang, S.J.: WO06110176 (2006).
78. Baselga J, Schöffski P, Rojo F, et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J Clin Oncol, 2006 ASCO Annu Meet Proc. Vol 24, No. 18S (June 20 Supplement), 2006: 3006.
79. Aventis Holdings Inc, Imclone Systems, Inc.: LU91117 (2004).
80. Salts LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) vs. cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol, 2005 ASCO Annu Meet Proc. Vol 23, No. 165, (June 1 Suppl), 2005: 3508.
81. Sahin, U., Tuereci, O., Usener, D. Fritz, S. Uherek, C., Brandenburg, G., Geppert, H.G., Schroeder, A.K., Thiel, P.: WO07059997 (2007).
82. Kussie, P., Ferguson, K.M.: WO06009694 (2006).